Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

(marketscreener.com) Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Breast Cancer were updated to include an addition involving neratinib .The updated NCCN Practice Guidelines for Breast Cancer include neratinib combinations as category 2B potential...https://www.marketscreener.com/quote/stock/PUMA-BIOTECHNOLOGY-INC-32676238/news/Puma-Biotechnology-s-NERLYNX-Included-in-NCCN-Clinical-Practice-Guidelines-for-the-Treatment-of-Bre-42868360/?utm_medium=RSS&utm_content=20230201